z-logo
open-access-imgOpen Access
Economic evaluation of the effectiveness of therapy for mastitis in cows with drugs of various pharmacological groups
Author(s) -
E.V. Nefedova
Publication year - 2021
Publication title -
veterinariâ i kormlenie
Language(s) - English
Resource type - Journals
ISSN - 1814-9588
DOI - 10.30917/att-vk-1814-9588-2021-4-11
Subject(s) - mastitis , udder , medicine , drug , culling , veterinary drug , veterinary medicine , zoology , herd , pharmacology , biology , chemistry , pathology , chromatography
With modern technologies of milk production, udder disease in cows is one of the most common. All forms of mastitis are classified as complex and unprofitable diseases that cause significant damage to the economy of dairy cattle breeding, which consists of premature culling of highly productive cows, milk during and after treatment with antibacterial drugs, the loss of highly productive offspring - calves, as well as the costs associated with diagnosis and treatment. The use of a drug containing argovit silver nanoparticles allows you to shorten the treatment period in the absence of damage from milk rejection after therapy. The study was conducted to study the cost-effectiveness of treatment of cow mastitis with drugs of various pharmacological groups. The animals were divided into experimental and control groups according to the principle of analogues. The experimental groups were treated with argovit in the form of a 10 % aqueous solution intracisternally, 10 ml, 1 time per day. The cows of the control groups were injected intracisternally with 5 g of the drug lactobai three times with an interval of 12 hours. The results of the research established a high economic effect of veterinary measures on 1 rub of costs for the treatment of subclinical, serous and catarrhal mastitis in cows with a drug containing argovit silver nanoparticles, which amounted to 5.4; 53.6 and 55.6 rubles, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here